Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A spectral-decomposition aging index for microplastics in aquatic environments.

Journal of hazardous materials·2026

Same author

Radiolabeled Mesoporous Silica Nanosystem Enables Long-Term Cell Tracking In Vivo.

Molecular pharmaceutics·2026

Same author

Integrative single-cell and spatial transcriptomic analysis reveals a lactate-driven crosstalk between NFATc4⁺ tumor cells and SPP1⁺ macrophages in glioblastoma.

Journal of translational medicine·2026

Same author

Efficacy of limaprost combined with unilateral biportal endoscopic surgery in the treatment of lumbar spinal stenosis: based on time effects and stratified analysis.

Frontiers in surgery·2026

Same author

Targeting the Gut Microbiota with Herbal Compounds from Traditional Chinese Medicine: A Mechanistic Synthesis of a Novel Therapeutic Approach for Ulcerative Colitis.

Journal of inflammation research·2026

Same author

Persistent NET states link lesion-related microbial signals to the cold tumor-related local restrictive environment: a context-dependent working model.

Cell communication and signaling : CCS·2026

Search research articles

Related Experiment Video

Updated: Mar 4, 2026

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

⁸⁹Zr/¹⁷⁷Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics.

Jingyue Gao¹, Tianyi Cen², Junyi Chen³

¹Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China.

Journal of Medicinal Chemistry

|March 3, 2026

Summary

Sortilin (SORT1) targeted antibody latozinemab was used to create novel theranostic radiopharmaceuticals. These agents show high specificity and therapeutic potential for SORT1-positive cancers, including melanoma.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

Related Experiment Videos

Last Updated: Mar 4, 2026

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

Area of Science:

Oncology
Radiopharmaceutical Science
Molecular Imaging

Background:

Sortilin (SORT1) is overexpressed in several cancers, making it a potential target for cancer therapy and diagnostics.
Current therapeutic strategies targeting SORT1 are limited, necessitating the development of novel approaches.

Purpose of the Study:

To develop and validate a theranostic pair targeting Sortilin (SORT1) for cancer treatment.
To evaluate the efficacy of SORT1-targeted radiopharmaceuticals in preclinical cancer models.

Main Methods:

Development of [⁸⁹Zr]Zr-DFO-latozinemab for PET imaging and [¹⁷⁷Lu]Lu-DOTA-latozinemab for therapy.
Assessment of SORT1 expression in various malignancies using transcriptional analysis and tissue microarrays.
Evaluation of radiopharmaceutical binding affinity, internalization, tumor uptake, and therapeutic efficacy in vitro and in vivo.

Main Results:

High SORT1 expression confirmed in melanoma and other malignancies.
[⁸⁹Zr]Zr-DFO-latozinemab demonstrated specific tumor visualization with high contrast.
[¹⁷⁷Lu]Lu-DOTA-latozinemab exhibited significant tumor accumulation and suppressed tumor growth through DNA damage induction.

Conclusions:

The study establishes the first Sortilin (SORT1)-directed theranostic radiopharmaceutical pair.
These agents show high specificity and therapeutic potency for SORT1-positive cancers, offering a promising new avenue for cancer management.